The most widely studied antiangiogenic therapeutic is bevacizumab, a humanised monoclonal antibody that binds with high affinity to VEGF-A preventing its binding to its receptor, thus inhibiting tumour vascular endothelial cell proliferation and angiogenesis, reducing vascular permeability, and promoting tumour blood vessel degradation [24]. The gene discussed is VEGFA; the disease is neoplasm.